Effectiveness and safety of rituximab for remission maintenance therapy in microscopic polyangiitis and granulomatosis with polyangiitis in Japan: A retrospective multicentre cohort study (J-CANVAS)
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag014 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Motoki Takeuchi und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Rituximab. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Rituximab (RTX) is a standard maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis. Its efficacy in Japan remains unclear, where microscopic polyangiitis (MPA) predominates and clinical characteristics differ from Western-dominated randomized controlled trial (RCT) populations.
Methods
Japanese patients with MPA or granulomatosis with polyangiitis (GPA) enrolled in a nationwide registry were included. Exposure was RTX use during maintenance therapy. The primary endpoint was major relapse–free survival at 104 weeks. The secondary endpoint was any relapse–free survival (major or minor) at 104 weeks. Baseline differences were adjusted using inverse probability of treatment weighting based on key demographic and disease-related covariates.
Results
A total of 389 patients were analysed, with 85 in the RTX group. The RTX group included a higher proportion of GPA cases (37/85 vs. 74/304), resulting in baseline imbalance. After inverse probability of treatment weighting, no major relapses were observed in the RTX group, whereas the major relapse–free survival at 104 weeks was 94.8% in the non-RTX group. The RTX group showed significantly higher any relapse–free survival at 104 weeks (95.4% versus 83.3%; HR for any relapse, 0.27; 95% CI, 0.09–0.74; P = .02).
Conclusions
Our findings suggest that RTX may be an effective option for remission maintenance in Japanese patients with MPA or GPA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
- Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan.
- Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
- Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Japan.
- Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
ORCID-Profile: Motoki Takeuchi, Yoshiyuki Abe, Ayako Makiyama, Masahiro Kogami, Satoshi Omura, Daiki Nakagomi, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Shintaro Hirata, Kiyoshi Matsui, Tohru Takeuchi, Kunihiro Ichinose, Ryo Yanai, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Takafumi Ito, Ayuko Takatani, Yoshia Miyawaki, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Ken Yamaji, Naoto Tamura
Zitieren
APA
Takeuchi, M., Abe, Y., Makiyama, A., Kogami, M., Omura, S., Nakagomi, D., Kadoya, M., Takizawa, N., Nomura, A., Kukida, Y., Kondo, N., Yamano, Y., Yanagida, T., Endo, K., Hirata, S., Matsui, K., Takeuchi, T., Ichinose, K., Yanai, R., …, & Tamura, N. (2026). Effectiveness and safety of rituximab for remission maintenance therapy in microscopic polyangiitis and granulomatosis with polyangiitis in Japan: A retrospective multicentre cohort study (J-CANVAS). Modern Rheumatology. https://doi.org/10.1093/mr/roag014
Vancouver
Takeuchi M, Abe Y, Makiyama A, Kogami M, Omura S, Nakagomi D, et al. Effectiveness and safety of rituximab for remission maintenance therapy in microscopic polyangiitis and granulomatosis with polyangiitis in Japan: A retrospective multicentre cohort study (J-CANVAS). Modern Rheumatology. 2026. doi:10.1093/mr/roag014
BibTeX
@article{Takeuchi2026,
author = {Takeuchi, Motoki and Abe, Yoshiyuki and Makiyama, Ayako and Kogami, Masahiro and Omura, Satoshi and Nakagomi, Daiki and Kadoya, Masatoshi and Takizawa, Naoho and Nomura, Atsushi and Kukida, Yuji and Kondo, Naoya and Yamano, Yasuhiko and Yanagida, Takuya and Endo, Koji and Hirata, Shintaro and Matsui, Kiyoshi and Takeuchi, Tohru and Ichinose, Kunihiro and Yanai, Ryo and Matsuo, Yusuke and Shimojima, Yasuhiro and Nishioka, Ryo and Okazaki, Ryota and Takata, Tomoaki and Ito, Takafumi and Moriyama, Mayuko and Takatani, Ayuko and Miyawaki, Yoshia and Kawahito, Yutaka and Ito-Ihara, Toshiko and Kida, Takashi and Yajima, Nobuyuki and Kawaguchi, Takashi and Yamaji, Ken and Tamura, Naoto},
title = {Effectiveness and safety of rituximab for remission maintenance therapy in microscopic polyangiitis and granulomatosis with polyangiitis in Japan: A retrospective multicentre cohort study (J-CANVAS)},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag014}
}
EUVIMED